1. 53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (April 2015) Authors: Platzbecker, U.; Germing, U.; Giagounidis, A.; Götze, K.; Kiewe, P.; Mayer, K.; Ottmann, O.; Radsak, M.; Wolff, T.; Haase, D.; Hankin, M.; Wilson, D.; Zhang, X.; Laadem, A.; Sherman, M.; Attie, K. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the Pace Study. (April 2017) Authors: Platzbecker, U.; Germing, U.; Götze, K.; Kiewe, P.; Wolff, T.; Mayer, K.; Chromik, J.; Radsak, M.; Wilson, D.; Zhang, X.; Laadem, A.; Sherman, M.; Attie, K.; Linde, P.; Giagounidis, A. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗